Caihe Law Firm recently achieved a favorable judgment for its client, Hangzhou-based Medical Technology Co., Ltd., in a patent invalidation administrative dispute before the Beijing Intellectual Property Court. The court ruled to revoke the rejection decision by the China National Intellectual Property Administration (CNIPA) and ordered a reexamination of the client’s invention patent application.

The case centered on a patent application (No. 202110438776.1) covering an AI-powered system for evaluating ovarian reserve function, which CNIPA had rejected for lack of inventive step. Our legal team focused on nuanced, evidence-based arguments aligned with global patent practice:

- We distinguished the client’s two‑marker model (age + AMH only, eliminating FSH) from prior art, emphasizing its finely calibrated age stratification (6 tiers) and AMH grading (10 tiers).

- We demonstrated that the specific coefficient settings (a, b, c) and classification logic were derived from extensive clinical validation, not routine optimization.

- We clarified that the prior art merely recognized AMH’s diagnostic value but provided no actionable teaching to build a reliable two‑marker predictive system, especially one validated at scale.

The court accepted our position, confirming the invention possessed non‑obviousness and inventive step—critical findings for biomedical algorithmic patents.

With disciplined legal reasoning and deep technical understanding, Caihe Law Firm delivers steady, results-driven intellectual property representation for innovative enterprises.